Skip to Content
Merck
CN

HIGFBMAG-53K

MILLIPLEX® Human IGF Binding Protein Panel

Configurable Human IGF Binding Protein 7-Plex Panel

Sign In to View Organizational & Contract Pricing.

About This Item

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

species reactivity

human

Quality Level

200

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

assay range

accuracy: 79%
(IGFBP-5), sensitivity: 0.01 ng/mL
(MinDC+2SD; IGFBP-1), sensitivity: 0.07 ng/mL
(MinDC+2SD; IGFBP-7), sensitivity: 0.12 ng/mL
(MinDC+2SD; IGFBP-6), sensitivity: 0.15 ng/mL
(MinDC+2SD; IGFBP-3), sensitivity: 0.96 ng/mL
(MinDC+2SD; IGFBP-4), sensitivity: 1.09 ng/mL
(MinDC+2SD; IGFBP-2), sensitivity: 9.87 ng/mL
(MinDC+2SD; IGFBP-5), standard curve range: 0.03-25 ng/mL
(IGFBP-1), standard curve range: 0.07-50  ng/mL
( IGFBP-3), standard curve range: 0.07-50 ng/mL
(IGFBP-7), standard curve range: 0.14-100 ng/mL
(IGFBP-6), standard curve range: 0.34-250 ng/mL
(IGFBP-2), standard curve range: 0.69-500 ng/mL
(IGFBP-4), standard curve range: 1.37-1000 ng/mL
(IGFBP-5), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-1), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-2), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-3), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-4), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-5), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-6), inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-7)

technique(s)

multiplexing: suitable

input

cell culture supernatant
serum

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Related Categories

General description

Insulin-like growth factor binding proteins (IGFBPs) regulate the bioavailability and activity of IGFs, playing critical roles in growth, metabolism, aging, and disease progression. This set of biomarkers—IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, and IGFBP7—provides a comprehensive view of IGF pathway modulation. These analytes are involved in cell proliferation, differentiation, apoptosis, and metabolic regulation, making them valuable for research in cancer, diabetes, aging, and endocrine disorders.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 7 analytes in human serum, plasma, or cell culture supernatants.

Analytes included: IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5, IGFBP6, IGFBP7

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

Features:

  • Multiplex magnetic bead-based assay for simultaneous quantification of 7 IGF binding proteins
  • Utilizes Luminex® xMAP® technology for high-throughput and reproducible results
  • Compatible with human serum, plasma, and tissue culture supernatants
  • High sensitivity and wide dynamic range for low-abundance detection
  • Includes all necessary reagents and standards for streamlined workflow
  • Verified for precision, reproducibility, and minimal cross-reactivity
Benefits:

  • Enables comprehensive profiling of IGF binding proteins involved in growth and metabolism
  • Reduces sample volume requirements while maximizing data output
  • Saves time and cost compared to running individual ELISAs
  • Supports research in endocrine signaling, cancer biology, and metabolic regulation
  • Provides reliable, reproducible data for both basic and translational research

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nasser M Al-Daghri et al.
Nutrition & diabetes, 8(1), 54-54 (2018-10-06)
Subjects with low vitamin D levels are at risk of cardiometabolic disease. The aim of this study was to identify novel serological markers linking vitamin D status with cardiometabolic profile in non-diabetic adults with obesity. For the discovery phase, we
Monika Bilic et al.
Endocrine connections, 8(6), 745-753 (2019-05-10)
Fetal growth restriction is linked to adverse health outcomes and is prevalent in low- and middle-income countries; however, determinants of fetal growth are still poorly understood. The objectives were to determine the effect of prenatal vitamin D supplementation on the
Arcangelo Liso et al.
Oncotarget, 8(37), 60826-60840 (2017-10-06)
Fever plays a role in activating innate immunity while its relevance in activating adaptive immunity is less clear. Even brief exposure to elevated temperatures significantly impacts on the immunostimulatory capacity of dendritic cells (DCs), but the consequences on immune response
Zaohuo Cheng et al.
Frontiers in aging neuroscience, 10, 414-414 (2019-01-09)
It is well known that Alzheimer's disease (AD) is one of the most common progressive neurodegenerative diseases; it begins gradually, and therefore no effective medicine is administered in the beginning. Thus, early diagnosis and prevention of AD are crucial. The
Francesca D'Addio et al.
Nature communications, 13(1), 684-684 (2022-02-05)
Loss of pancreatic beta cells is a central feature of type 1 (T1D) and type 2 (T2D) diabetes, but a therapeutic strategy to preserve beta cell mass remains to be established. Here we show that the death receptor TMEM219 is

Related Content

Multiplexing Metabolic Syndrome Biomarkers | MILLIPLEX® Assays

Multiplex immunoassays, such as MILLIPLEX® multiplex metabolic assays, are critical in metabolic syndrome research because they provide a full picture of the different conditions related to it, like diabetes and obesity, as well as save time and sample volume.

Tips & Tricks | Guide to Multiplexing | MILLIPLEX® Assays

Uncover tips and tricks to multiplexing in this guide from the experts. Learn how you can enhance the power of your research with MILLIPLEX® multiplexing, including industry guidance for immunoassays, multiplexing tips, one-day MILLIPLEX® multiplex assays for limited lab time, and more.

The Power of Biomarker Analysis
Quality Control Range Sheet- IGFBP-114 and IGFBP-214
See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service